| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Photodynamic Therapy (PDT) | Dermatologic System | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Photodynamic Therapy (PDT) | Dermatologic System | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Photodynamic Therapy (PDT) | Dermatologic System |
Recent Updates
Recently added Catalysts
Biofrontera Inc.$1.1
-0.04 (-3.51%)
C 44Pipeline Score Undervalued Pharma · Clinical
Market Cap
13.19 M
EPS
-1.11
P/E Ratio
-0.93 $
Value Trade
146.06 K
SEC Financials
Q1 2026Dilution Risk
Revenue
10.08 M
R&D Expenses
900.00 K
Operating CF
-70.00 K
Total Assets
24.79 M
Total Liabilities
18.72 M
Equity
6.07 M
D/E Ratio
12,345
-15.02 %
Week
-23.84 %
1 Month
-5.17 %
3 Month
3.5 %
6 Month
-99.01 %
5 Year
-99.01 %
All Time
Cash Data
Cash Position
6.32 M
Monthly Burn
23.00 K
Runway
273 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
351.87 K
52 Week Range
0.55 - 1.19
% held by Insiders
14.96 %
% held by Institutions
19.89 %
Enterprise Value
14.59 M
Total Shares
12.81 M
Short %
0.25 %
Float Shares
11.31 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Biofrontera Inc.
469Total events
3Upcoming
115Tier-1 (high impact)
2017 – 2026Coverage
Upcoming catalysts 3
Event history 466
Q3 2026
◆sNDA SubmissionAmeluz®ApprovedRegulatory Filing
Planned sNDA submission to FDA for label expansion
actinic keratoses on the extremities, neck, and trunksource ↗
Q3 2026
◆FDA Feedback ReceivedAmeluz®ApprovedFDA Meeting
Phase 2 acne vulgaris results to be presented to FDA
moderate to severe acne vulgarissource ↗
May 28, 2026
◆Oral PresentationPresentation
Biofrontera webcast presentation at Lytham Partners Spring 2026 Investor Conference
May 14, 2026
◆Quarterly UpdateCorporate
Biofrontera Inc. First Quarter 2026 Financial Results and Business Update Conference Call
May 14, 2026
▲Topline ReadoutAmeluz®ApprovedClinical Data
Positive top-line results from Phase 3 trial of Ameluz PDT for AK on extremities, neck, and trunk
mild to moderate actinic keratoses (AKs) on extremities, neck, and trunksource ↗
May 14, 2026
▲Primary Endpoint MetAmeluz®ApprovedClinical Data
Primary endpoint met in Phase 3 trial of Ameluz PDT for AK on extremities, neck, and trunk
mild to moderate actinic keratoses (AKs) on extremities, neck, and trunksource ↗
Q2 2026
◆sNDA SubmissionAmeluz®ApprovedRegulatory Filing
Planned sNDA submission to FDA for AK on extremities, neck and trunk
actinic keratoses on extremities, neck and trunksource ↗
Q2 2026
◆Trial CompletionAmeluz®ApprovedTrial
12-month follow-up phase expected to conclude
actinic keratoses on extremities, neck and trunksource ↗
Mar 19, 2026
◆Quarterly UpdateCorporate
Biofrontera Inc. to report Q4 and full year 2025 financial results and host conference call
Mar 19, 2026
▲Topline ReadoutAmeluz®ApprovedClinical Data
Positive Phase 3 topline results for Ameluz PDT in AK on extremities, neck, trunk
actinic keratoses on extremities, neck, trunksource ↗
Mar 19, 2026
▲FDA Filing AcceptedAmeluz®ApprovedRegulatory Filing
FDA accepted sNDA for Ameluz PDT in sBCC
superficial basal cell carcinoma (sBCC)source ↗
Mar 19, 2026
●Enrollment CompleteAmeluz®ApprovedTrial
Database lock of Phase 1 PK study for FDA filing on treatment field up to 240 cm2
actinic keratoses on extremities, neck, trunksource ↗
Drug Pipeline Intelligence
C44
Pipeline Score $198M
Pipeline ValueUndervalued
Valuation Signal4
Drugs Scored15.0x
rNPV / MCap Top 65%
Micro Cap (rank 320 of 911)
Percentile RankBiofrontera Inc. carries a moderate pipeline score (44/100), with $1.1B risk-adjusted pipeline value, led by BF-200 ALA in Basal Cell Carcinoma (BCC) (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BF-200 ALA and red light LED lamp Small molecule | Actinic Keratoses | Phase 3 | NCT05662202 | 50% | $871M | COMPLETED | 220 | SLOW | B (61) | Jul 1, 2026 | MODERATE_RISK | HIGH Jul 7, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Ameluz® | moderate to severe acne vulgaris | Phase 2b | 2026-03-09 | inflammatory lesion reduction: 57.97%; vehicle inflammatory lesion reduction: 36.51%; m IGA success rate: 25%; vehicle m IGA success rate: 21.4%; lesion reductions: inflammatory 19.7, non inflammatory 23.1, total 42.7; vehicle lesion reductions: inflammatory 15.4, non inflammatory 16.5, total 31.9; patient satisfaction: would choose again 85.7%, rated outcome good or very good 71.4% Read More | Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris Read More | |
Ameluz® | moderate to severe acne vulgaris | Phase 2b | 2026-03-09 | inflammatory lesion reduction: 57.97%; vehicle inflammatory lesion reduction: 36.51%; m IGA success rate: 25%; vehicle m IGA success rate: 21.4%; lesion reductions: inflammatory 19.7, non inflammatory 23.1, total 42.7; vehicle lesion reductions: inflammatory 15.4, non inflammatory 16.5, total 31.9; patient satisfaction: would choose again 85.7%, rated outcome good or very good 71.4% Read More | Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris Read More | |
Ameluz® | moderate to severe acne vulgaris | Phase 2b | 2026-03-09 | inflammatory lesion reduction: 57.97%; vehicle inflammatory lesion reduction: 36.51%; m IGA success rate: 25%; vehicle m IGA success rate: 21.4%; lesion reductions: inflammatory 19.7, non inflammatory 23.1, total 42.7; vehicle lesion reductions: inflammatory 15.4, non inflammatory 16.5, total 31.9; patient satisfaction: would choose again 85.7%, rated outcome good or very good 71.4% Read More | Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BFRI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BFRI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BFRIBiofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Biofrontera Inc. will participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026. The event will feature a webcast presentation at 11:00 a.m. ET and virtual one-on-one meetings with investors. This engagement highlights Biofrontera's focus on investor relations and its commitment to the biopharmaceutical sector.
Read more →BFRIBiofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update
Biofrontera Inc. reported a 17% increase in revenues for Q1 2026, reaching $10.1 million. The company also saw improvements in gross margins, which rose to approximately 80%. Despite an operating loss of $4.3 million, Biofrontera announced positive results from its Phase 3 and Phase 2b clinical trials, and regained compliance with Nasdaq listing requirements. The company is focused on achieving sustained profitability and growth.
Read more →BFRIBiofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis
Biofrontera has launched its second annual 'Hats On' campaign to raise awareness of actinic keratosis (AK) from May 18-24, 2026. This social media initiative encourages participants to wear hats and share photos to highlight the importance of sun protection. With over 58 million Americans affected by AK, the campaign aims to promote preventive measures against skin cancer.
Read more →BFRIBiofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026
Biofrontera Inc. will announce its financial results for Q1 2026 on May 14, 2026, after market close. The company will also conduct a conference call at 11:00 a.m. ET to discuss these results and provide a business update. Biofrontera specializes in photodynamic therapy for dermatological conditions.
Read more →BFRIBiofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA (
Biofrontera Inc. reported record financial results for the fourth quarter and full year of 2025, reflecting significant revenue growth and improved operating metrics. The company achieved revenues of $17.1 million in Q4 2025, a 36% increase from the previous year, and transitioned to a more favorable cost structure with gross margins rising to 82.4%. Additionally, Biofrontera showcased positive results from its Phase 2b clinical trial for acne treatment and a supportive FDA review of its supplemental new drug application. Despite some continued losses, the company expressed optimism about sustained profitability in the upcoming years.
Read more →BFRIBiofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
Biofrontera Inc. announced positive results from its Phase 2b trial of Ameluz® PDT for moderate to severe acne vulgaris. The study demonstrated greater reductions in inflammatory lesions compared to a vehicle gel, with a 3-hour incubation regimen showing the most promise. The company plans to present these findings to the FDA in Q3 2026 to discuss further development.
Read more →BFRIBiofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026
Biofrontera Inc. announced that it will report its financial results for the fourth quarter and full year of 2025 on March 19, 2026, after the market closure. A conference call is scheduled for the same day at 10:00 a.m. ET, where the company will discuss the results and provide a business update. The announcement emphasizes the company's focus on photodynamic therapy (PDT) and its products for treating dermatological conditions.
Read more →BFRIU.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable
Biofrontera Inc. announced that the U.S. Patent Trial and Appeal Board ruled all challenged claims of Sun Pharma's U.S. Patent No. 11,697,028 as unpatentable. This decision follows Sun Pharma's infringement claims against Biofrontera. The ruling allows Biofrontera to continue its focus on photodynamic therapy development without the burden of this patent. Sun Pharma may appeal the decision.
Read more →BFRI▲ +6.6%on this news· ran to +19% by day 1
Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities
Biofrontera Inc. has announced the database lock of its Phase 1 pharmacokinetics study for Ameluz®, aimed at treating actinic keratoses on the trunk and extremities. The study's data, alongside positive Phase 3 results, will support a supplemental New Drug Application to the FDA for expanding treatment indications. This could allow for broader treatment areas, enhancing Ameluz®'s market potential.
Read more →BFRIBiofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma
Biofrontera Inc. announced that the FDA has accepted its supplemental New Drug Application for Ameluz® in treating superficial basal cell carcinoma (sBCC). The FDA identified no deficiencies in the filing and set a PDUFA target action date of September 28, 2026. If approved, this will expand Ameluz®'s use beyond actinic keratosis, addressing a significant unmet medical need.
Read more →BFRIBiofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint
Biofrontera Inc. announced positive results from its Phase 3 clinical trial of Ameluz® PDT for treating actinic keratoses on the extremities, neck, and trunk. The study showed a significant complete clearance rate of 45.6% for Ameluz® compared to 16.7% for the vehicle. The company plans to submit a supplemental New Drug Application to the FDA in Q3 2026.
Read more →BFRIBiofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth
Biofrontera Inc. announced preliminary revenue results for Q4 2025, projecting revenues between $17.0 million and $17.5 million, marking a record high for the company. The anticipated year-over-year growth for Q4 is approximately 35%. The full year revenue is expected to be between $41.5 million and $42.0 million, reflecting an 11% to 13% increase. The company attributes its success to strong execution and customer engagement.
Read more →BFRIBiofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones
Biofrontera Inc. has successfully locked the databases for two clinical studies evaluating Ameluz® PDT, marking a significant milestone ahead of expected data and regulatory events in 2026. The studies focus on treating actinic keratosis and moderate to severe acne vulgaris. Data is anticipated in February 2026, with plans for regulatory submissions based on positive outcomes.
Read more →BFRI▲ +5.6%on this news
Biofrontera Inc. Completes Transfer of Ameluz and RhodoLED FDA approval and Associated Intellectual Property Portfolio
Biofrontera Inc. has successfully completed the transfer of FDA approvals for Ameluz and the RhodoLED Lamp Series, including associated intellectual property rights. The move includes the assignment of 11 granted US patents and 10 pending patent applications, enhancing the company's regulatory control. Furthermore, Biofrontera has initiated applications for 19 international patents. This strategic transfer, which follows a recent $11.0 million investment, positions the company to independently manage clinical development and marketing operations for their products in the US.
Read more →BFRIBiofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT
Biofrontera Inc. has submitted a supplemental New Drug Application (sNDA) to the FDA for Ameluz®-PDT, aiming to treat superficial basal cell carcinoma (sBCC). The Phase 3 study showed a 65.5% clearance rate in patients treated with Ameluz® compared to only 4.8% with placebo. The company seeks to expand its product label based on these promising results.
Read more →BFRI▼ -8.6%on this news
Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update
Biofrontera Inc. reported its Q3 2025 financial results, showing a revenue decline of 22% compared to Q3 2024. The company is optimistic about achieving its full-year sales objectives, driven by strong demand for its Ameluz-PDT treatment. A recent acquisition of U.S. rights for Ameluz is expected to enhance profitability. Despite increased legal costs, the company anticipates significant revenue growth in the fourth quarter.
Read more →BFRI▼ -6.9%on this news
Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M
Biofrontera Inc. has announced the sale of its US license for Xepi® (ozenoxacin) Cream to Pelthos Therapeutics for up to $10 million. The deal includes an initial payment of $3 million, with further payments contingent on revenue milestones. This divestiture is expected to enhance Biofrontera's financial position and support its focus on photodynamic therapy products.
Read more →BFRI▲ +6.4%on this newsshared move
Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025
Biofrontera Inc. will report its financial results for the third quarter of 2025 on November 12, 2025, following the close of U.S. markets. A conference call is scheduled for November 13, 2025, at 10:00 AM ET to discuss the results and provide a business update. The company specializes in dermatological products and is focused on treatments for skin conditions including non-melanoma skin cancers and acne.
Read more →BFRI▲ +11.9%on this news
Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG
Biofrontera Inc. has finalized the acquisition of all U.S. assets related to Ameluz® and RhodoLED® from Biofrontera AG. This transaction includes the New Drug Application, manufacturing rights, and intellectual property. The new earnout structure is designed to reduce costs and enhance profitability, with expectations for growth in the coming years. The deal was supported by an $11 million investment from existing investors.
Read more →BFRIBiofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
Biofrontera Inc. will participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025. The event will include a webcast presentation at 1:15 p.m. ET and virtual one-on-one meetings with investors. This participation underscores Biofrontera's focus on investor relations and its commitment to discussing its dermatological products.
Read more →BFRI▼ -5.7%on this newsshared move
Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program
Biofrontera Inc. has appointed Lytham Partners to lead its investor relations and shareholder communication efforts. This strategic move aims to broaden Biofrontera's investor base and enhance its market visibility. The company has recently made significant progress, including securing $11 million in funding and restructuring its operations to position itself for profitability. Lytham Partners will support Biofrontera in communicating its value proposition effectively.
Read more →BFRI▲ +6.2%on this news
Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk
Biofrontera Inc. has announced the completion of the active treatment phase in its Phase 3 clinical trial for Ameluz® PDT, aimed at treating actinic keratoses on the extremities, neck, and trunk. All 172 patients have transitioned to a 12-month follow-up phase, expected to conclude in Q2 2026. The company plans to submit a supplemental New Drug Application to the FDA pending positive outcomes.
Read more →BFRIBiofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris
Biofrontera Inc. announced the completion of the last patient in its Phase 2b trial for Ameluz® in treating moderate to severe acne vulgaris. The trial aims to evaluate the effectiveness of Ameluz® combined with red-light Photodynamic Therapy (PDT). Positive results could lead to a Phase III program and FDA submission in 2026.
Read more →BFRIBiofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update Woburn, MA
Biofrontera Inc. reported a 15% increase in Q2 2025 revenue at $9.0 million, alongside a $17.7 million total for the first half, marking a 12% year-over-year growth. The company secured an additional $11 million in funding and restructured its agreement with Biofrontera AG, gaining U.S. rights to vital patents and new drug applications. Despite these positives, Biofrontera experienced an increase in net loss due to higher legal expenses and continued negative EBITDA. The company aims to leverage these developments to enhance sales effectiveness and expand treatment options for its products.
Read more →BFRIBiofrontera Inc. Appoints George Jones as Chief Commercial Officer
Biofrontera Inc. has appointed George Jones as Chief Commercial Officer, effective August 25, 2025. In this role, he will manage the company's commercial functions and report to CEO Dr. Hermann Luebbert. This appointment follows Biofrontera's acquisition of rights to Ameluz® and RhodoLED® for the U.S. market, which is expected to enhance the company's financial position.
Read more →BFRIBiofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025
Biofrontera Inc. announced that it will report its financial results for the second quarter of FY 2025 on August 13, 2025. The results will be released after market hours, followed by a conference call on August 14 to discuss the outcomes and business updates. The company specializes in dermatological products, particularly in the treatment of skin conditions. This reporting highlights the company's continuous engagement with stakeholders and its oversight of fiscal performance.
Read more →BFRI▲ +18.3%on this news
Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment Biofrontera Inc. has signed an agreement to acquire all US assets related to Ameluz and RhodoLED includi
Biofrontera Inc. has restructured its relationship with Biofrontera AG through an agreement to acquire all U.S. assets related to Ameluz and RhodoLED for $11 million. This transaction significantly reduces the royalty rate Biofrontera will pay, aiming to increase profitability and market agility. The new structure transfers full responsibility for manufacturing and commercial operations to Biofrontera Inc., enhancing its operational capabilities in the dermatology market. The investment is expected to propel the company towards profitability as it advances its FDA submission for treating superficial basal cell carcinoma.
Read more →BFRI▲ +6.1%on this news
BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG WOBURN, Mass. (
Biofrontera Inc. is currently in negotiations with Biofrontera AG to possibly combine operations or amend their licensing agreement. This could result in a transfer of responsibilities and a reduction in the price of Biofrontera Inc.'s licensed products in the U.S. However, the specifics of any potential agreement have yet to be determined and are subject to various conditions, which emphasizes the uncertainty surrounding the negotiations.
Read more →BFRI▲ +16.3%on this news
Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book
Biofrontera Inc. announced the patent approval for its propylene glycol-free formulation of Ameluz®, now listed in the FDA's Orange Book. This recognition by the FDA confirms the formulation's safety and efficacy standards while extending patent protection until December 2043. The new formulation aims to reduce allergic reactions for sensitive patients without compromising treatment effectiveness. The FDA's inclusion solidifies Biofrontera's commitment to patient-centric innovation in dermatological therapies.
Read more →BFRI▲ +16.3%on this news
SUPPLEMENT DATED JUNE 3, 2025 TO THE PROXY STATEMENT FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS OF BIOFRONTERA INC. To Be Held on
Biofrontera Inc. has filed a supplement to its Proxy Statement ahead of the 2025 Annual Meeting of Stockholders scheduled for June 12, 2025. This amendment clarifies the voting rights of stockholders, particularly regarding Proposals No. 2 and 3, which the NYSE now classifies as 'routine' matters. As a result, banks and brokers can vote on these proposals without the need for specific instructions from stockholders. The company encourages all stockholders to participate and vote as their input is crucial for the upcoming meeting.
Read more →BFRI▼ -7.2%on this news
Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update Conference call begins at 10:00 a.m. Eastern time on Friday
Biofrontera Inc. reported a 9% increase in revenues for the first quarter of 2025, totaling $8.6 million. The company achieved significant milestones in its clinical development, including the completion of patient enrollment in multiple Phase 3 and Phase 2b trials for its key product, Ameluz. However, the company's cash reserves have decreased notably to $1.8 million, and it reported a net loss of $4.2 million for the period. Executive leadership expressed optimism about the company's growth trajectory and market strategy moving forward.
Read more →BFRIBiofrontera Inc. Announces New Patent Protection on Ameluz until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris
Biofrontera Inc. announced that its revised formulation of Ameluz® has received patent approval extending its protection until December 2043. Additionally, the company has successfully enrolled 120 patients in a Phase 2b clinical trial to evaluate Ameluz's effectiveness for treating moderate to severe acne vulgaris. This trial is pivotal as it seeks to expand the drug's indications beyond its current use. The U.S. acne treatment market is valued at approximately $5.7 billion and is expected to grow, underscoring the demand for innovative therapies in this field.
Read more →BFRIBiofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis
Biofrontera Inc. (NASDAQ:BFRI) and Almirall have launched the Hats On Challenge to raise awareness for actinic keratosis (AK) ahead of Global AK Awareness Day on May 24. This social media initiative aims to educate the public about AK, which can lead to skin cancer if left untreated. Participants are encouraged to wear hats and share videos, with funds generated supporting The Skin Cancer Foundation. The campaign highlights the importance of prevention and treatment of this common skin condition.
Read more →BFRI▼ -16.5%on this news
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update Conference scheduled for Friday
Biofrontera Inc. reported record financial results for fiscal year 2024, achieving total revenues of $37.3 million, marking a 9.5% increase from the previous year. This growth was largely attributed to increased sales of the Ameluz product and the new RhodoLED XL Lamp. Despite the positive revenue growth, the company still incurred a net loss of $(17.8) million. The CEO highlighted a strategy refocus for 2025 aimed at enhancing customer support and expanding treatment options, bolstered by recent FDA approvals and clinical trial progress.
Read more →BFRIBiofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk
Biofrontera Inc. has announced the completion of patient enrollment in its Phase 3 clinical trial for Ameluz, aimed at treating actinic keratoses on the extremities, neck, and trunk. This trial is expected to finish its treatment phase by September 2025, with follow-up concluding by Q2 2026. If successful, Biofrontera plans to submit a supplemental New Drug Application to the FDA in the second half of 2026. The study aims to provide a much-needed treatment option for a common skin condition that can lead to cancer if untreated.
Read more →BFRIBiofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025
Biofrontera Inc. announced that it will report its financial results for the fourth quarter and full year 2024 on March 21, 2025. The results will be released before market opening, followed by a conference call at 10:00 AM Eastern Time on the same day. Biofrontera specializes in dermatological products, particularly focusing on photodynamic therapy (PDT) treatments. The company is actively involved in clinical trials to expand its product indications.
Read more →BFRI▲ +6.3%on this news
Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz -Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
Biofrontera Inc. has announced the completion of a key milestone in its Phase 3 study of Ameluz for the treatment of superficial basal cell carcinoma (sBCC), with the last patient completing a one-year follow-up. The study, which involved 187 patients, demonstrated highly statistically significant results for efficacy. Data from this follow-up will be included in Biofrontera's upcoming FDA submission expected in Q3 2025. The company emphasizes the importance of continued long-term follow-up for patients to assess the treatment's effectiveness over time.
Read more →BFRIBiofrontera Inc. Announces 100 RhodoLED XL Machines Now Placed in US Market
Biofrontera Inc. has successfully placed its 100th RhodoLED XL machine in the US market, following its commercial launch in June 2024. The device, approved by the FDA for photodynamic therapy (PDT) in combination with Ameluz, has experienced significant uptake from dermatology offices. Notably, the RhodoLED XL allows for treating larger surface areas, potentially improving patient care and office efficiency. The company has received enthusiastic responses from users, leading to positive momentum in adoption rates.
Read more →BFRI▲ +14.6%on this news· ran to +30% by day 3
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note WOBURN, Mass. (
Biofrontera Inc. has successfully closed a $4.2 million senior secured convertible note, which matures in 2027. The financing was secured by the company's assets and will support various operational and strategic initiatives. The note features a 10% annual interest rate and allows for conversion into common shares under specific conditions. This capital will aid in Biofrontera's growth as it focuses on its dermatological treatments and commercial developments.
Read more →BFRI▼ -11.5%on this news· ran to -29% by day 3
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase wo
Biofrontera Inc. reported a revenue increase of 1.5% for Q3 2024, reaching $9.0 million, affected by shipment delays due to Hurricane Milton. The overall year-to-date revenue grew by 5.6% to $24.8 million. Despite the obstacles, the company's product Ameluz achieved record sales volume, and the RhodoLED XL has seen strong adoption. Following recent FDA approval for increased Ameluz dosage, Biofrontera is moving forward with plans to expand its commercial strategy and prepare for future FDA filings.
Read more →BFRI▲ +31.7%on this news
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz -Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) First Phase 3 PDT study in patients with sBC
Biofrontera Inc. announced highly significant results from its Phase 3 study of Ameluz in treating superficial basal cell carcinoma (sBCC). The study, involving 187 patients, showed a success rate of 65.5% for complete clearance of targeted lesions, compared to only 4.8% with placebo. Results were statistically significant across all endpoints, with high patient satisfaction noted. The company plans to submit its dossier to the FDA following a one-year follow-up phase, expected to complete in December.
Read more →BFRIBiofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz -Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
Biofrontera Inc. has announced the database lock for its Phase 3 study of Ameluz photodynamic therapy in treating superficial basal cell carcinoma (sBCC). This marks a critical point in the clinical trial, concluding data collection and initiating final analysis. The trial, which involved 186 patients, aims to evaluate the efficacy and safety of Ameluz-PDT in combination with the BF-RhodoLED lamp. Following the completion of patient follow-up expected by December 2024, the company plans to submit data to the FDA in early 2025.
Read more →BFRI▼ -9.5%on this news· ran to -26% by day 3
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment Approval allows for larger field treatment of actinic keratosis (AK) on face and scalp with A
The FDA has approved Biofrontera Inc.'s supplemental New Drug Application allowing the use of up to three tubes of Ameluz, a topical gel for treating actinic keratosis (AK). This approval provides healthcare professionals more flexibility to treat larger areas on the face and scalp, improving patient care. Supported by two Phase 1 safety studies, the safety profile of Ameluz remains strong, ensuring minimal risks during treatment. Biofrontera is now working towards securing reimbursement from Medicare and commercial payers for this update.
Read more →BFRI▼ -7.3%on this news
Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update Woburn, MA /
Biofrontera Inc. (NASDAQ:BFRI) reported its financial results for Q2 2024, highlighting revenue growth to $7.8 million, up from $5.8 million in Q2 2023, and a reduced net loss of $257 thousand compared to $9.8 million the previous year. The company successfully launched the RhodoLED XL, which received FDA approval in conjunction with Ameluz. Additionally, Biofrontera took control of its clinical trials for Ameluz in the U.S. to improve operational efficiency. However, costs remain high, and the company continues to seek financing for future growth.
Read more →BFRI▼ -5.3%on this news
Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED XL Lamp
Biofrontera Inc. has launched the FDA-approved RhodoLED XL lamp, enhancing photodynamic therapy for actinic keratoses. This innovative device allows for a larger treatment area and offers improved features over existing lamps. The first shipments have already been sent out, with encouraging feedback from dermatology practices. CEO Dr. Hermann Luebbert emphasizes the product's commitment to superior patient care and innovation.
Read more →BFRI▼ -5.1%on this news
Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED XL Lamp The RhodoLED XL is approved by the FDA in combination with Ameluz (aminolevulinic acid hydrochloride) topical gel, 10% for ph
Biofrontera Inc. has announced the launch of the RhodoLED XL Lamp, an FDA-approved device designed for photodynamic therapy in treating actinic keratoses on the face and scalp. The lamp, launched on June 10, 2024, features enhanced capabilities, including a larger illumination area and an intuitive user interface. The company has already shipped three units in its first week and received positive feedback from dermatology practices. This launch underscores Biofrontera's commitment to innovation in dermatological treatments.
Read more →BFRI▼ -6.2%on this news
Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update Conference call begins at 10:00 a.m. Eastern time on Thursday, May16, 2024 WOBURN, MA / ACCESSWIRE /
Biofrontera Inc. reported its first-quarter financial results for 2024, showing total revenues of $7.9 million, a 9% decrease from the previous year. The decrease is attributed primarily to healthcare reimbursement issues triggered by a significant data breach. Despite operational challenges, the company successfully completed a private placement raising $8 million and reduced the transfer price for its product Ameluz. The company expects sales of the new RhodoLED XL lamp to commence in the second quarter of 2024, and it will also assume management of U.S. clinical trials for Ameluz starting in June 2024.
Read more →BFRIBiofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants WOBURN, MA / ACCESSWIRE /
Biofrontera Inc. has announced the achievement of two critical milestones related to its Series B-3 Convertible Preferred Stock Warrants. The company successfully achieved over 5% year-on-year revenue growth and implemented a new customer relationship management system with high adoption rates. These accomplishments position the company to secure $8 million in additional funding pending SEC approval. Shareholder approval to increase authorized capital further enhances Biofrontera's financial stability and growth prospects.
Read more →BFRI▼ -5.4%on this news· ran to +63% by day 3
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals
Biofrontera Inc. has announced its 2024 Annual Meeting of Stockholders will take place on June 12, 2024, with the record date set for April 22, 2024. Stockholders intending to submit proposals must do so by specified deadlines, including April 19 for inclusion in the proxy statement. The company has indicated the need for compliance with SEC regulations for proposal submissions. This meeting provides an opportunity for stockholders to engage with the company regarding its operational and strategic initiatives.
Read more →BFRI▼ -18.7%on this news
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update Conference call begins at 10:00 a.m. Eastern time on Monday
Biofrontera Inc. reported record financial results for the fiscal year 2023, achieving total revenues of $34.1 million, a 19% increase from the previous year. The company announced a strategic restructuring of its organization, which resulted in an 8% reduction in operating expenses in the fourth quarter. Key accomplishments included FDA approval for an enhanced formulation of Ameluz and completion of patient enrollment in a Phase 3 clinical study. Despite these achievements, the company incurred a net loss of $20.1 million, prompting ongoing efforts to improve cost management and operational efficiency.
Read more →BFRI▼ -7.5%on this news· ran to -18% by day 3
Biofrontera Inc. Announces Closing of Private Placement of Up To $16.0 Million priced at market per Nasdaq rules Ø Company closed financing of $8.0 million with an additional $8.0 million second tranche tied to mi
Biofrontera Inc. has announced the successful closing of an $8.0 million private placement, with a second tranche potentially bringing total funding to $16.0 million. This funding is intended to bolster the company's R&D activities and support the commercialization of its dermatology products. The transaction involves issuing Series B-1 and Series B-3 Convertible Preferred Stock to institutional investors, with contingent milestones affecting the additional tranche. Stockholder approval will be required for specific stock conversions and future growth endeavors.
Read more →BFRI▲ +53.4%on this newsshared move
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG Ø Ameluz transfer price to Biofrontera AG reduced significantly Ø Control of all US clinical trials of Ameluz transfers to Bi
Biofrontera Inc. has announced the restructuring of its supply agreement with Biofrontera AG, significantly reducing the transfer price of Ameluz from 50% to 25% for the years 2024 and 2025. Effective June 1, 2024, Biofrontera Inc. will also assume control of all US clinical trials for Ameluz, which is expected to enhance cost management and trial efficiency. In the long-term, these changes may lead to the expansion of Ameluz's label and increased revenue, potentially reaching profitability by 2025 with regulatory reviews underway for further indications.
Read more →BFRIBiofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz to Permit Up to Three Tubes per Use FDA has set a target action date of
Biofrontera Inc. has announced that it has submitted a supplemental New Drug Application (sNDA) for its product Ameluz, seeking FDA approval to allow the use of up to three tubes per treatment for actinic keratosis (AK). The FDA has issued a letter indicating no filing review issues and will commence its substantive review, with a target action date set for October 4, 2024. Two Phase 1 studies support the sNDA, demonstrating safety profiles consistent with the single tube use. The company anticipates that approval could enhance the convenient treatment of AK, benefiting both patients and dermatologists.
Read more →BFRIBiofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023
Biofrontera Inc. has announced preliminary unaudited revenues for the fourth quarter and full year 2023, indicating record high revenues of approximately $33.8 million to $34.3 million, representing a 19% increase from 2022. The anticipated revenue for the fourth quarter is between $10.4 million and $10.9 million, marking a 5% gain over the same period last year. Although sales have shown strong growth, especially in the latter half of the year, the company notes that fourth quarter sales growth fell slightly short of expectations. Biofrontera will provide more detailed financial results in March 2024.
Read more →BFRIBiofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update Conference call begins at 10:00 a.m. Eastern time on Friday
Biofrontera Inc. reported its financial results for Q3 2023, showing total revenues of $8.9 million, a remarkable 106% increase compared to the same period last year. The company also provided updates on its business, including successful Phase 1 study results for Ameluz-PDT and FDA approval for a new Ameluz formulation. Despite these positive developments, Biofrontera faced a net loss of $6.3 million for the quarter and rising operating expenses. The company expects continued revenue growth and aims to become cash flow positive within approximately a year and a half.
Read more →BFRI▲ +23.7%on this news
Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
Biofrontera Inc. announced a registered direct offering amounting to $4.5 million with a specific institutional investor. The agreement involves the sale of 1,205,000 shares of common stock and warrants for an additional 1,807,000 shares at an exercise price of $3.55. The expected closing date for the offering is around November 2, 2023. Proceeds from this offering will be used for working capital and general corporate purposes.
Read more →BFRI▼ -8.6%on this news· ran to -19% by day 3
Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz Patent Application Filed with Potential to Extend Ameluz Protection to 2043 WOBURN, Mass. (
Biofrontera Inc. has received FDA approval for a new formulation of Ameluz, aimed at treating actinic keratosis. The new formulation, which replaces propylene glycol with safer ingredients, is expected to enhance patient safety and overall treatment effectiveness. This approval reflects the company's commitment to innovation in photodynamic therapy. Furthermore, Biofrontera has filed a patent application that could extend Ameluz's protection until 2043, providing significant market advantages.
Read more →BFRIBiofrontera Inc. Announces Preliminary Third Quarter Revenues Revenues Increased 101% to 108% Over the Prior-Year Quarter Affirms Guidance for Full-Year Revenue Growth of at Least 25% over 2022 WOBURN, Mass. (
Biofrontera Inc. announced preliminary third-quarter revenues of approximately $8.7 million to $9.0 million, representing a significant increase of approximately 101% to 108% compared to the same period last year. The company affirms its guidance for full-year revenue growth of at least 25% over 2022, highlighting a successful sales strategy that includes increased adoption of photodynamic therapy. The results, driven by higher sales of Ameluz and BF-RhodoLED lamps, indicate positive momentum as they approach the year's strongest quarter. Final results are expected to be reported in November 2023.
Read more →BFRIINDEX TO FINANCIAL STATEMENTS Page Audited Financial Statements as of and for the Years Ended
The article primarily consists of references to financial statement categories and related party transactions associated with BFRI. It lists various financial and accounting classifications without providing substantial news or updates about the company's performance or future outlook. The lack of concrete financial data may hinder investor understanding of BFRI's current state. Overall, the information appears to be procedural and lacks engaging content.
Read more →BFRIBiofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business Update Conference call begins at 8:30 a.m. Eastern time today WOBURN, Mass. (
Biofrontera Inc. has reported its financial results for the second quarter of 2023, highlighting a 31% increase in total revenues to $5.8 million. Despite this growth, the company recorded a net loss of $9.8 million and a significant decrease in cash reserves, which dropped to $4.5 million. The company has appointed Hermann Luebbert as CEO and announced advancements in their clinical studies and product innovations, including a lower-cost portable PDT lamp. Biofrontera anticipates a revenue growth of at least 25% for the full year 2023.
Read more →BFRIBiofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31% Management Reaffirms Full-Year 2023 Revenue Growth of at least 25% over Prior Year WOBURN, Mass. (
Biofrontera Inc. announced preliminary revenues for the second quarter of 2023, projecting an increase of 26% to 31% compared to the same period in 2022, with total anticipated revenues between $5.7 million and $5.9 million. The company also reaffirmed its full-year revenue growth expectations, aiming for at least a 25% increase over the previous year. The increase in revenues was attributed to the growing adoption of photodynamic therapy for treating actinic keratosis. Final financial results are expected to be reported in August 2023.
Read more →BFRIBiofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors WOBURN, Mass. (
Biofrontera Inc. has appointed Dr. Heikki Lanckriet to its Board of Directors, bringing over 20 years of experience in the life sciences industry. This appointment follows a settlement agreement with Biofrontera AG and is seen as a strategic move to strengthen the company's governance. Dr. Lanckriet's expertise is expected to aid in the clinical trials aimed at enhancing the use of Ameluz, a product aimed at treating actinic keratosis and other dermatological conditions. His prior leadership roles and knowledge are anticipated to contribute to Biofrontera's growth and innovation in the dermatology market.
Read more →BFRIBiofrontera Inc. Announces 1-for-20 Reverse Stock Split WOBURN, Mass. (
Biofrontera Inc. has announced a 1-for-20 reverse stock split to be executed after trading on July 3, 2023. This move aims to comply with Nasdaq's minimum bid price requirement and is expected to make the company's shares more attractive to investors. Following the split, shares will be adjusted accordingly, with outstanding equity awards proportionately modified as well. The company's publicly traded warrants will remain unchanged but will also be adjusted to reflect the new split ratio.
Read more →BFRIBiofrontera Inc. Begins Development of a Portable Photodynamic Therapy Lamp for Use with Ameluz -PDT WOBURN, Mass. (
Biofrontera Inc. has embarked on the development of a new portable photodynamic therapy lamp to be utilized with its flagship product, Ameluz. This initiative aims to create a low-cost option that facilitates easier usage for clinicians, particularly in settings with limited office space. The company has partnered with patent holders to enhance its PDT technology and expects to start prototyping later this month. The portable lamp could improve access to treatment for actinic keratosis patients, a condition affecting millions in the U.S.
Read more →BFRIBiofrontera Inc. Names Founder and Executive Chairman Hermann Luebbert as Chief Executive Officer WOBURN, Mass. (
Biofrontera Inc. has appointed Hermann Luebbert, the founder and current Executive Chairman, as the new Chief Executive Officer. Luebbert, who has a deep background in the company and in biopharmaceuticals, plans to actively drive the company's growth and seek profitability. His leadership will focus on expanding Biofrontera's research and development capabilities, particularly in photodynamic therapy and other dermatological products. This move comes as part of a broader strategy to enhance the company's market position and manage its own clinical studies more effectively.
Read more →BFRI▼ -28.6%on this news
Biofrontera Inc. Reports First Quarter 2023 Financial Results and Provides a Business Update Conference call begins at 8:30 a.m. Eastern time today WOBURN, Mass. (
Biofrontera Inc. reported its financial results for Q1 2023, revealing total revenues of $8.7 million which reflects a decrease from $9.8 million during the same quarter last year. Despite record-high monthly sales volumes in January and February, a net loss of $7.5 million was reported, indicative of rising operational costs and a lack of customer buy-in compared to the previous year. The company has bolstered its sales force and affirmed expectations for at least 25% revenue growth for the full year 2023, alongside ongoing clinical trials for its product Ameluz.
Read more →BFRIBiofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results
Biofrontera, Inc. reported its financial results for the fourth quarter and full year of 2022, highlighting a record annual revenue for Ameluz with a 12% increase over pre-COVID levels. The company achieved total revenues of $28.7 million for the year, a 19% growth compared to 2021. Despite reporting a loss of $640,000 for the year, the loss was significantly reduced from $37.7 million in 2021, reflecting improved financial performance. Management expressed confidence in future growth potential, forecasting at least a 25% revenue increase for 2023, further supported by expanding their salesforce and continued educational initiatives in the dermatological market.
Read more →BFRI▲ +12.2%on this news
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2022 WOBURN, Mass. (
Biofrontera Inc. has announced preliminary, unaudited revenues for the fourth quarter and the full year of 2022, projecting Q4 revenues between $10.2 million and $10.4 million, marking a 12% increase year-over-year. The company's total revenue estimate for 2022 is around $28.7 million to $28.9 million, representing a 20% growth compared to 2021. CEO Erica Monaco emphasized the importance of these results as Biofrontera focuses on enhancing their commercial strategy, particularly for their product Ameluz, and building momentum in 2023. Final financial results will be reported in March 2023, subject to adjustments from the preliminary estimates.
Read more →BFRI▼ -11.2%on this news
Biofrontera Inc. Announces Voting Results from 2022 Annual Meeting of Stockholders
WOBURN, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the final voting results from its 2022 Annual Meeting of Stockholders held on December 1
Read more →BFRIBiofrontera Inc. to Participate in Benchmark’s 11th Annual Discovery One-on-One Investor Conference
WOBURN, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company will be participating in Benchmark’s 11th Annual Discovery One-on-One I
Read more →BFRI▲ +5.1%on this newsshared move
BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON WEDNESDAY, NOVEMBER 30, MONDAY, DECEMBER 5, FRIDAY, DECEMBER 9, AND MONDAY, DECEMBER 19 2022
Woburn, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. ("Biofrontera" or the "Company") (NASDAQ: BFRI), announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation
Read more →BFRIBiofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz -PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
WOBURN, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the launch of a randomized, double-blind, vehicle-controlled, multicenter Phase 3 clinic
Read more →BFRIBiofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update
Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial results for the three
Read more →BFRIBiofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass. (
Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update call begins at 11:00 a.m. Eastern time today Mass. (November 14, 2022) - Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological produc
Read more →BFRI▲ +11.3%on this newsshared move
Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022
WOBURN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2022 before
Read more →BFRI▼ -7%on this newsshared move
Biofrontera Inc. Fully Exercises Recently Acquired Options to Purchase Shares of Biofrontera AG WOBURN, Mass. (
Inc. Fully Exercises Recently Acquired Options to Purchase Shares of Biofrontera AG Mass. (November 8, 2022) - Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the exercise in full of
Read more →BFRIBiofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG
Sets company up to realize full commercial potential in fast growing U.S. market Supports mutually beneficial interests between Biofrontera Inc and Biofrontera AG WOBURN, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company speci
Read more →BFRIBiofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG Sets company up to realize full commercial potential in fast growing U.S. market Supports mutually beneficial interests between
Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG Sets company up to realize full commercial potential in fast growing U.S. market Supports mutually beneficial interests between Biofrontera Inc and Biofrontera AG WOBURN, Mass. (October 31, 2022)
Read more →BFRIBiofrontera Inc. Names Fred Leffler as Chief Financial Officer WOBURN, Mass. (
Inc. Names Fred Leffler as Chief Financial Officer Mass. (October 24, 2022) - Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Fred Leffler as Chief Financial Officer, eff
Read more →BFRIBiofrontera Inc. Names Fred Leffler as Chief Financial Officer
WOBURN, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Fred Leffler as Chief Financial Officer, effective immediately. Mr. Leffler
Read more →BFRIBiofrontera Inc. to Present at the LD Micro Main Event XV Investor Conference
WOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that Erica Monaco, Chief Executive Officer, will be presenting and meeting with register
Read more →BFRIBiofrontera Inc. to Sponsor the 2022 Fall Clinical Dermatology Conference
Four Posters Highlighting Results from Investigator-Initiated and Company-Sponsored Research with Ameluz to be Presented WOBURN, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermato
Read more →BFRI▲ +5.2%on this newsshared move
Biofrontera Inc. Adopts Limited Duration Shareholder Rights Plan
WOBURN, Mass., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that its Board of Directors has adopted a limited duration shareholder r
Read more →BFRI▲ +5.2%on this newsshared move
PRESS RELEASE
Inc. Adopts Limited Duration Shareholder Rights Plan Mass. (October 14, 2022) - Biofrontera Inc. (Nasdaq: BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that its Board of Directors has adopted
Read more →BFRIBIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON FRIDAY OCTOBER 14, AND TUESDAY OCTOBER 18, 2022
WOBURN, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. ("Biofrontera" or the "Company") (NASDAQ: BFRI), announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor prese
Read more →BFRIBiofrontera Inc. Announces Preliminary Product Revenues for the Third Quarter of 2022
WOBURN, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary unaudited product revenues for the three and nine months ended September 30,
Read more →BFRIBiofrontera Inc. Announces Preliminary Product Revenues for the Third Quarter of 2022 WOBURN, Mass. (
Inc. Announces Preliminary Product Revenues for the Third Quarter of 2022 Mass. (October 5, 2022) - Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary unaudited product reven
Read more →BFRI▲ +5.2%on this news
Biofrontera Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
WOBURN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that Erica Monaco, Chief Executive Officer, will present at the Roth Inaugural Healthca
Read more →BFRIBiofrontera Inc.’s Marketing Campaign and Website for Ameluz Won 2022 PM360 Trailblazer Awards
WOBURN, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that PM360, a publication for marketing decision makers in the pharmaceutical, biotech,
Read more →BFRIBiofrontera Inc. Names Gerard DiGirolamo as National Sales Director
WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Gerard DiGirolamo as National Sales Director. In this newly created positi
Read more →BFRI▲ +5.9%on this news
Biofrontera Inc. Announces Notice of Allowance for Nanoemulsion Composition-of-Matter U.S. Patent
Company also granted special designation that enables expedited review of a recent U.S. patent application relating to novel PDT illumination protocols WOBURN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in
Read more →BFRI▼ -5%on this news
Biofrontera Inc.’s Leslie Hopkins Named PM360 Trailblazer 2022 Brand Champion for Dermatology
WOBURN, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that PM360, a publication for marketing decision makers in the pharmaceutical, biotech,
Read more →BFRIBiofrontera Inc. Reports Second Quarter 2022 Financial Results and Provides a Business Update Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass. (
Inc. Reports Second Quarter 2022 Financial Results and Provides a Business Update call begins at 11:00 a.m. Eastern time today Mass. (August 12, 2022) - Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological product
Read more →BFRIBiofrontera Inc. Reports Second Quarter 2022 Financial Results and Provides a Business Update
Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today financial results for the three
Read more →BFRIBiofrontera Inc. to Report Second Quarter Financial Results on August 12, 2022
WOBURN, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2022 before the o
Read more →BFRI▲ +7%on this newsshared move
Biofrontera Inc. Announces Patent in Australia for Novel Illumination Protocols Granted to Biofrontera Bioscience GmbH
Patent Improves Differentiated Profile of Ameluz-PDT by Expected Reduced Pain Intensity while Maintaining Efficacy WOBURN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatologica
Read more →BFRI▼ -12.2%on this newsshared move
Biofrontera Inc. Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement WOBURN, Mass. (
Inc. Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement Mass. (July 27, 2022) - Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it has entered into
Read more →BFRI▲ +7.6%on this news
Biofrontera Inc. Announces Preliminary Product Revenues for the Second Quarter of 2022 WOBURN, Mass. (
Inc. Announces Preliminary Product Revenues for the Second Mass. (July 12, 2022) - Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today preliminary unaudited product revenues for the six a
Read more →BFRI▲ +7.6%on this news
Biofrontera Inc. Announces Preliminary Product Revenues for the Second Quarter of 2022
WOBURN, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today preliminary unaudited product revenues for the six and three months ended June 30, 2022.
Read more →BFRIBiofrontera, Inc. Recognized for Rapid Sales Growth, Innovative Therapies and Marketing Excellence
Named Among the 10 Fastest-Growing Life Sciences Companies to Watch in 2022 by CIOCoverage Magazine New Ameluz® Marketing Campaign Receives Gold 2022 Award of Excellence from The Communicator Awards WOBURN, Mass, June 09, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI)
Read more →BFRIBiofrontera Inc. to Participate in The Benchmark Healthcare House Call Virtual 1x1 Conference
WOBURN, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company will be participating in The Benchmark Healthcare House Call Virtual 1x1
Read more →BFRI▲ +7.3%on this news
Biofrontera Inc. Announces Closing of $9.4 Million Private Placement
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the closing of its previously-announced $9.4 million private placement with a single inst
Read more →BFRI▼ -5.4%on this newsshared move
Biofrontera Inc. Announces Pricing of $9.4 Million Private Placement
WOBURN, MA., May 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera, Inc. (Nasdaq: BFRI; BFRIW), announced today that it has entered into a securities purchase agreement with a single institutional investor for the purchase of 3,419,000 shares of its common stock (or common stock equivalen
Read more →BFRI▼ -5.4%on this newsshared move
Biofrontera Inc. Announces Pricing of $9.4 Million Private Placement WOBURN, MA.
Inc. Announces Pricing of $9.4 Million Private Placement MA. May 16, 2022 - Biofrontera, Inc. (Nasdaq: BFRI; BFRIW), announced today that it has entered into a securities purchase agreement with a single institutional investor for the purchase of 3,419,000 shares of its common
Read more →BFRIBiofrontera Inc. Reports First Quarter 2022 Financial Results and Provides a Business Update
Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial result
Read more →BFRIBiofrontera Inc. Reports First Quarter 2022 Financial Results and Provides a Business Update Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass. (
Inc. Reports First Quarter 2022 Financial Results and Provides a Business Update call begins at 11:00 a.m. Eastern time today Mass. (May 13, 2022) - Biofrontera Inc. (Nasdaq: BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatolog
Read more →BFRIBiofrontera Inc. to Report First Quarter Financial Results on May 13, 2022
WOBURN, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, will report financial results for the three months ended March 31, 2022 before the opening of the U.S. fi
Read more →BFRI▼ -6.2%on this news· ran to -19% by day 3shared move
Biofrontera Inc. to Showcase Actinic Keratosis Treatments at the Music City Symposium for Cosmetic Advances & Laser Education
Live Demonstration of New RhodoLED® XL to be Featured WOBURN, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today its sponsorship of the 17th Editio
Read more →BFRIBiofrontera Launches New Patient-Focused Websites for Ameluz and Xepi
Ameluz® for the treatment of actinic keratoses now at www.ameluz.com Xepi® for the treatment of impetigo now at www.xepicream.com WOBURN, Mass. , April 21, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercializatio
Read more →BFRI▲ +34.1%on this news
Biofrontera Inc. Announces FDA Approval of Biofrontera Pharma GmbH as a Contract Laboratory for Ameluz
Significantly Improves Manufacturing Efficiency, Quality Control and Supply Reliability WOBURN, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced toda
Read more →BFRI▲ +14.4%on this newsshared move
APRIL 8, 2022 Biofrontera Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update Introduces 2022 financial guidance Conference call begins at 11:00 a.m. Eastern time
Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update 2022 financial guidance call begins at 11:00 a.m. Eastern time today Mass. (April 8, 2022) - Biofrontera Inc. (Nasdaq: BFRI) (the "Company"), a biopharmaceutical company specializin
Read more →BFRI▲ +14.4%on this newsshared move
Biofrontera Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update
Introduces 2022 financial guidance Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological prod
Read more →BFRIBiofrontera Inc. Announces Preliminary Product Revenues for the First Quarter of 2022
WOBURN, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today preliminary, unaudited product revenues for the quarter ended March 31, 2022. Product
Read more →BFRI▲ +5.4%on this newsshared move
Biofrontera Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on April 8, 2022
WOBURN, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it will report financial results for the three months and full year ended December 31,
Read more →BFRI▲ +17.5%on this news
Biofrontera to Showcase Actinic Keratoses and Impetigo Treatments at the 2022 American Academy of Dermatology Annual Meeting
Company to have a strong onsite presence at the world’s largest scientific conference for dermatologists, with approximately 10,000 medical professionals expected to attend WOBURN, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical com
Read more →BFRIBiofrontera Inc. Announces FDA Orange Book Listing of U.S. Patent for BF-RhodoLED XL, Extends Protection of Ameluz -PDT Through October 2040
WOBURN, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the previously granted U.S. patent No. 11,235,169 (the ’169 patent) for the BF-Rho
Read more →BFRI▲ +14.7%on this newsshared move
Biofrontera Inc. to Present at the 34th Annual Roth Conference
WOBURN, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announces today that Erica Monaco, Chief Executive Officer, will be presenting and meet
Read more →BFRI▼ -7.5%on this newsshared move
Biofrontera Inc. Appoints Kevin D. Weber to its Board of Directors
WOBURN, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Kevin D. Weber to its Board of Directors, expanding Board
Read more →BFRI▼ -5.5%on this news
Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs
Leverkusen, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera AG (the “Company”) (Nasdaq: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, decided today its American Depositary Shares (“ADS”) should be delisted from the Nasdaq Capital Market
Read more →BFRI▲ +26.8%on this news
Biofrontera Inc. provides Update on Patient Recruitment for Phase III Study for the Treatment of sBCC with Ameluz -PDT
WOBURN, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, is pleased to provide an update on the patient recruitment for the phase III clinical st
Read more →BFRI▼ -6.7%on this news· ran to -30% by day 3
Biofrontera Inc. Issues Letter to Shareholders Highlighting 2021 Successes and Key Elements of the Strategic Plan for 2022 and Beyond
WOBURN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today issued the following letter from CEO Erica Monaco and Executive Chairman of the Bo
Read more →BFRI▼ -7.7%on this news· ran to -24% by day 3shared move
Biofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021
WOBURN, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenue for the quarter and full year ended Decem
Read more →BFRI▲ +22%on this newsshared move
Biofrontera Inc. Announces Participation in Two Dermatology Conferences in January
WOBURN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that it plans to participate in the following two dermatology conference
Read more →BFRI▼ -13.9%on this news· ran to -26% by day 3
Biofrontera Inc. announces reduction of Biofrontera AG shareholding to less than 50% through warrant exercises
WOBURN, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced that through the exercise of outstanding warrants the majority ownership of Biofrontera AG was
Read more →BFRI▲ +27%on this news
Biofrontera Inc. Announces Enrollment of First Subject in Phase 2b Clinical Trial Evaluating Ameluz + BF-RhodoLED in Moderate-to-Severe Acne
WOBURN, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the first subject has been enrolled in the Phase 2b study performed by Biofrontera
Read more →BFRI▲ +12.1%on this news· ran to +56% by day 3shared move
Biofrontera Inc. Announces Notice of Allowance for U.S. Method-of-Use Patent on PDT-lamp
WOBURN, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowa
Read more →BFRIBiofrontera Inc. Enrolls First Subject in Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz
WOBURN, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the first subject has been enrolled in a Phase 1 study to evaluate the safety and t
Read more →BFRI▲ +21.2%on this newsshared move
Biofrontera Inc. Announces Closing of $15 Million Private Placement
WOBURN, MA., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI; BFRIW) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the closing of a private placement with a single institutional inve
Read more →BFRI▲ +21.2%on this newsshared move
Biofrontera Inc. Announces Notice of Allowance for U.S. Patent on Innovative Illumination Protocol
WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowa
Read more →BFRI▼ -15.6%on this news· ran to -40% by day 3shared move
Biofrontera Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update Conference call at 4:30 p.m. Eastern time today
Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update call at 4:30 p.m. Eastern time today Mass., November 30, 2021 - Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announc
Read more →BFRI▼ -15.6%on this news· ran to -40% by day 3shared move
Biofrontera Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
Conference call at 4:30 p.m. Eastern time today WOBURN, Mass., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today financial results for the three and nin
Read more →BFRI▼ -10.1%on this news· ran to -34% by day 3shared move
Biofrontera Inc. Pricing of $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules WOBURN, MA.
Inc. Pricing of $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules MA. November 29, 2021- Biofrontera, Inc. (Nasdaq: BFRI; BFRIW), today announced today that it has entered into a securities purchase agreement with a single institutional investor for the purc
Read more →BFRI▼ -10.1%on this news· ran to -34% by day 3shared move
Biofrontera Inc. Pricing of $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules
WOBURN, MA., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Biofrontera, Inc. (Nasdaq: BFRI; BFRIW), today announced today that it has entered into a securities purchase agreement with a single institutional investor for the purchase of 2,857,143 shares of its common stock (or common stock eq
Read more →BFRI▲ +6.5%on this news· ran to +187% by day 3shared move
Biofrontera Inc. to Report Third Quarter Financial Results on November 30, 2021
WOBURN, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, will report financial results for the three and nine months ended September 30, 2021 before the opening
Read more →BFRI▲ +5.1%on this news· ran to +106% by day 3shared move
Biofrontera AG announces mediation results
Leverkusen, Germany, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (ISIN: DE0006046113) has been in mediation proceedings with Mr. Wilhelm K. T. Zours and Deutsche Balaton AG for a year in order to find a solution for the settlemen
Read more →BFRI▼ -8%on this newsshared move
Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021
Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2021. Key financial figur
Read more →BFRI▼ -8.3%on this newsshared move
Biofrontera Kicks Off US Clinical Study Program for Ameluz
WOBURN, MA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the start of a clinical study program focused on optimizing and expanding t
Read more →BFRI▼ -8.3%on this newsshared move
Biofrontera AG announces initiation of clinical studies
Leverkusen, Germany, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that two clinical studies for its prescription drug Ameluz® in the United States are being st
Read more →BFRIBiofrontera AG: Conference call to discuss third quarter 2021 financial results to be held on November 18, 2021
Leverkusen, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first nine months ended September 30, 2021 on Wednesday
Read more →BFRI▼ -5.3%on this news· ran to -22% by day 3
Biofrontera Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Warrants
WOBURN, MA., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (“Biofrontera” or the “Company”) (Nasdaq: BFRI; BFRIW), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the closing of its underwritten initial public off
Read more →BFRIBiofrontera Inc. Announces Pricing of $18.0 Million Initial Public Offering
WOBURN, MA. , Oct. 28, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (“Biofrontera” or the “Company”) (Nasdaq: BFRI; BFRIW), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the pricing of its underwritten initial public of
Read more →BFRIBiofrontera Inc. Announces Pricing of $18.0 Million Initial Public Offering WOBURN, MA.
Inc. Announces Pricing of $18.0 Million Initial Public Offering MA. October 28, 2021- Biofrontera Inc. ("Biofrontera" or the "Company") (Nasdaq: BFRI; BFRIW), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the prici
Read more →BFRIBiofrontera AG receives FDA-approval of the BF-RhodoLED XL lamp
Leverkusen, Germany, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced the approval of the new red-light source for photodynamic therapy (PDT), the BF-RhodoLE
Read more →BFRIBiofrontera reports preliminary approximate revenues for the month of September 2021
Leverkusen, Germany, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of September 2021. The Company’s prelimina
Read more →BFRIBiofrontera reports preliminary revenue for the month of August 2021
Leverkusen, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of August 2021. The Company’s preliminary
Read more →BFRIBiofrontera reports financial results for the six months ended June 30, 2021
Leverkusen, Germany, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the six months ended June 30, 2021. Key financial figures and
Read more →BFRIBiofrontera AG: Conference call to discuss half-year 2021 financial results to be held on August 20, 2021
Leverkusen, Germany, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2021 on Thursday, Augus
Read more →BFRIBiofrontera reports preliminary revenue for the month of July 2021
Leverkusen, Germany, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of July 2021. The Company’s preliminary, u
Read more →BFRIBiofrontera enters into license and supply agreement with Medac for the marketing of Ameluz in Poland
Leverkusen, Germany, July 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Medac Gesellschaft für klinische Spezialpräparate mbH. (Medac), signed an exclusive license and supply ag
Read more →BFRIBiofrontera Inc. seeks IPO in the USA
Leverkusen, Germany, July 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG currently holds 100 % of the shares of the US-based Biofrontera Inc. Biofrontera AG had already announced that opportunities for capital raises were being evaluated including a potential initial public offerin
Read more →BFRIBiofrontera reports preliminary revenue for the month of June 2021
Leverkusen, Germany, July 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of June 2021. The Company’s preliminary, u
Read more →BFRIBiofrontera provides update on clinical developments
Leverkusen, Germany, June 22, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today provides an update on its clinical developments. In February and March 2021, the Company announc
Read more →BFRIBiofrontera reports preliminary revenue for the month of May 2021
Leverkusen, Germany, June 07, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of May 2021. The Company’s preliminary, un
Read more →BFRIBiofrontera reports Q1 2021 financial results
Leverkusen, Germany, May 11, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2021. Q1 2021 key financial
Read more →BFRIBiofrontera reports preliminary revenue for the month of April 2021
Leverkusen, Germany, May 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of April 2021. The Company’s preliminary, u
Read more →BFRIBiofrontera AG: First quarter conference call to be held on May 12, 2021
Leverkusen, Germany, May 03, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first quarter 2021 on Tuesday, May 11, 2021. Conferenc
Read more →BFRIBiofrontera reports results for the 2020 financial year
Leverkusen, Germany, April 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its consolidated results for the fiscal year ended December 31, 2020. At the same time,
Read more →BFRIBiofrontera announces preliminary revenue for Q1 2021
Leverkusen, Germany, April 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the first quarter 2021. The Company’s preliminary u
Read more →BFRIBiofrontera announces conference call to be held on April 13, 2021 to discuss fiscal year 2020 financial results
Leverkusen, Germany, March 31, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the fiscal year 2020 on Monday, April 12, 2021. Conferenc
Read more →BFRIBiofrontera submits application for FDA approval of new BF-RhodoLED XL lamp
Leverkusen, Germany, March 31, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced the submission for approval of a new, significantly larger red-light source for photod
Read more →BFRIBiofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24.7 million
Leverkusen, Germany, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, announces the closing of the capital increase resolved by the annual general meeting o
Read more →BFRIBiofrontera submits study report of pharmacokinetics study to FDA
Leverkusen, Germany, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces the submission of an application to the U.S. Food and Drug Administration (FDA) to amend the
Read more →BFRIBiofrontera AG Announces Pricing of US$8.9 Million Firm Commitment Public Offering of American Depositary Shares
NOT FOR DISTRIBUTION OUTSIDE THE UNITED STATES Leverkusen, Germany, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, today announced the pricing of a U.S.
Read more →BFRIBiofrontera AG: Ludwig Lutter appointed new Chief Financial Officer effective March 1, 2021
Leverkusen, Germany, Feb. 02, 2021 (GLOBE NEWSWIRE) -- The Supervisory Board of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces a change in the company's Management Board. Effective March 1, 2021,
Read more →BFRIBiofrontera announces preliminary revenue figures for the full year 2020
Leverkusen, Germany, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the full year 2020. Biofrontera Group's preliminary
Read more →BFRIBiofrontera enters into a license and supply agreement with Galenica AB for the marketing of Ameluz in Scandinavia
Leverkusen, Germany, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Galenica AB, Malmö, Sweden, today signed an exclusive license and supply agreement for the marketing of b
Read more →BFRIBiofrontera AG resolves mandatory conversion of subordinated mandatory convertible bonds
Leverkusen, Germany, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, has issued a 1.00% qualified subordinated mandatory convertible bond 2020/2021 (ISIN: DE000A3E4548 / WK
Read more →BFRIBiofrontera reports third quarter and first nine months 2020 results
Leverkusen, Germany, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today published its results for the third quarter ended September 30, 2020. In addition, the Company pr
Read more →BFRIBiofrontera announces conference call to be held on November 12, 2020 to discuss Q3 2020 financial results
Leverkusen, Germany, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its unaudited financial results for the third quarter ended September 30, 2020 on Wed
Read more →BFRIBiofrontera AG: Receives reasons from the Federal Court of Justice for overturning ruling of the Cologne Higher Regional Court
Leverkusen, Germany, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, had announced on September 22, 2020, that in a ruling from September 22, 2020, the German Federal Supre
Read more →BFRIBiofrontera reports preliminary unaudited sales revenue for the third quarter of 2020
Leverkusen, Germany, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports preliminary unaudited revenue for the third quarter of fiscal year 2020. The Biofrontera
Read more →BFRIBiofrontera AG reports completion of the clinical phase of the pharmacokinetics study
Leverkusen, Germany, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, reports the completion of the clinical phase (last subject last visit) of the pharmacokinetics study (P
Read more →BFRIBiofrontera AG: German Federal Supreme Court overturns ruling of the Cologne Higher Regional Court
Leverkusen, Germany, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that in ruling on September 22, 2020, the German Federal Supreme Court overturned a decision
Read more →BFRIBiofrontera AG plans mediation to resolve (legal) disputes
Leverkusen, Germany, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-Group”), an international biopharmaceutical company, today has reached a mutual agreement with Mr. Wilhelm K.T. Zours and Deutsc
Read more →BFRIBiofrontera AG to participate in two upcoming conferences
Leverkusen, Germany, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be participating virtually in two upcoming conferences. On September 17, 2020, members of Biofro
Read more →BFRIBiofrontera report results for the first six months of 2020
Leverkusen, Germany, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today published its results for the first six months ended June 30, 2020. In addition, the Company prov
Read more →BFRIBiofrontera announces conference call to be held on August 27, 2020 to discuss half-year 2020 financial results
Leverkusen, Germany, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2020 on Wednesday, Augu
Read more →BFRIBiofrontera AG announces subscription price for 1.00 % qualified subordinated mandatory convertible bond 2020/2021
Leverkusen, Aug. 10, 2020 (GLOBE NEWSWIRE) -- The Executive Board of Biofrontera AG (shares of Biofrontera AG ISIN: DE0006046113) has decided on 27 July 2020, with the approval of the Supervisory Board, to issue a 1.00 % qualified subordinated mandatory convertible bond 2020/2021
Read more →BFRIBiofrontera AG resolves to issue qualified subordinated mandatory convertible bonds
Leverkusen, Germany, July 27, 2020 (GLOBE NEWSWIRE) -- The Management Board of Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), today resolved, with the approval of the Supervisory Board, to issue a qualified subordinated mandatory convertible bond subject to the
Read more →BFRIBiofrontera reports preliminary unaudited sales revenue for the first six months of 2020
Leverkusen, Germany, July 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-Group”), an international biopharmaceutical company, today reports preliminary unaudited revenue for the first six months of fisc
Read more →BFRIBiofrontera confirms financing need
Leverkusen, Germany, June 30, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today confirmed the financing requirements to maintain ongoing business operations. During a hearing b
Read more →BFRIBiofrontera reports Q1 2020 financial results
Leverkusen, May 19, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2020 and provided an update on recent
Read more →BFRIBiofrontera dismisses case against DUSA Pharmaceuticals, Inc. in California state court
Leverkusen, Germany, May 13, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or “Biofrontera”), an international biopharmaceutical company, today comments on certain litigation in California state court between the Company and
Read more →BFRIBiofrontera announces conference call to be held on May 20, 2020 to discuss first quarter 2020 financial results
Leverkusen, Germany, May 12, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its unaudited financial results for the first quarter 2020 on Tuesday, May 19, 2020.
Read more →BFRIBiofrontera Reports Full Year 2019 Financial Results
Leverkusen, Germany, April 20, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the full year ended December 31, 2019 and provided an update
Read more →BFRIBiofrontera AG enters into exclusive license agreement with Maruho Co., Ltd.
Leverkusen, Germany, April 20, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, has signed today an exclusive license agreement (the "Agreement") with Maruho Co, Ltd
Read more →BFRIBiofrontera reports preliminary unaudited sales revenue for the first three months of 2020
Leverkusen, Germany, April 17, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports preliminary unaudited revenue for the first three months of fiscal year 2020. The preli
Read more →BFRIBiofrontera AG to propose resolution for ordinary capital increase to the Annual General Meeting
Leverkusen, Germany, April 16, 2020 (GLOBE NEWSWIRE) -- The Annual General Meeting of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) shall be held on May 28, 2020. Today, the Company has decided to propose to the Annual General Meeting a resolution for an ordinary c
Read more →BFRIBiofrontera announces conference call to be held on April 21, 2020 to discuss full year 2019 financial results
Leverkusen, Germany, April 09, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the full year 2019 on Monday, April 20, 2020. Conference
Read more →BFRIBiofrontera AG withdraws subscription offers for mandatory convertible bonds
Leverkusen, Germany, March 23, 2020 (GLOBE NEWSWIRE) -- On February 26, 2020, the Management Board resolved to issue up to 1,600,000 of the 0.5% qualified subordinated mandatory convertible bonds 2020/2024 (ISIN: DE000A254RS9) ("Bonds 2020/2024") with a nominal value of EUR 5.00
Read more →BFRIBiofrontera implements comprehensive measures to reduce costs during COVID-19 pandemic
Leverkusen, Germany, March 20, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced today that it has adopted comprehensive measures to reduce costs during the global COVID-19
Read more →BFRIBiofrontera AG signs non-binding term sheet for licensing agreement for Ameluz in Poland with medac GmbH Sp. z o.o.
Leverkusen, Germany, March 13, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) today signed a non-binding term sheet for an exclusive license agreement with medac GmbH Sp. z o.o., the Polish branch of medac Gesellschaft für klinische Spezialp
Read more →BFRIBiofrontera AG extends subscription period for mandatory convertible bonds
Leverkusen, Germany, March 12, 2020 (GLOBE NEWSWIRE) -- On February 26, 2020, Management Board resolved to issue up to 1,600,000 of the 0.5% qualified subordinated mandatory convertible bonds 2020/2024 (ISIN: DE000A254RS9) ("Bonds 2020/2024") with a nominal value of EUR 5.00 each
Read more →BFRIBiofrontera entered into binding term sheet with Maruho Co., Ltd.
Leverkusen, Germany, March 03, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), an international biopharmaceutical company, announces that it has entered into a Binding Term Sheet with Maruho Co, Ltd, Osaka, Japan ("Maruho"), which sets ou
Read more →BFRIBiofrontera provides clinical development updates
Leverkusen, Germany, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today provides an update on its clinical developments. On February 3, 2020, the Company announced that
Read more →BFRIBiofrontera announces 1-year follow-up results for its phase III study of photodynamic therapy for actinic keratosis on the extremities and trunk/neck
Leverkusen, Germany, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced follow-up results for its Phase III clinical study evaluating the safety and efficacy o
Read more →BFRIBiofrontera announces preliminary sales figures for the full year 2019, record sales in the 4th quarter
Leverkusen, Germany, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced its results for the first nine months ended September 30, 2019. At the same time, the g
Read more →BFRIBiofrontera strengthens commercial focus with reorganization of its US business
Leverkusen, Germany, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced a new organizational structure of its American subsidiary Biofrontera Inc. to strengthe
Read more →BFRIBiofrontera to Participate in Upcoming Investor Conferences
Leverkusen, Germany, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced its participation at the following events: Event: Deutsches Eigenkapitalforum / Analys
Read more →BFRIBiofrontera Reports Third Quarter 2019 Financial Results and Revises Guidance
Leverkusen, Germany, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced its results for the first nine months ended September 30, 2019. At the same time, the g
Read more →BFRIBiofrontera Announces Conference Call on November 19, 2019 to Discuss Third Quarter 2019 Financial Results
Leverkusen, Germany, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first nine months ended September 30, 2019 on November
Read more →BFRIBiofrontera Receives Award at Fall Clinical Dermatology Conference 2019
Leverkusen, Germany, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, was presented with the "Poster of the Day" award at the renowned Fall Clinical Dermatology Conference i
Read more →BFRIBiofrontera reports preliminary unaudited sales revenue for the first nine months of 2019
Leverkusen, Germany, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-group”), an international biopharmaceutical company, today reports preliminary unaudited revenue for the third quarter of fiscal
Read more →BFRIBiofrontera to present at the Baader Investment Conference
Leverkusen, Germany, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced that Prof. Dr. Hermann Lübbert, Biofrontera’s CEO, will be presenting at the Baader Investme
Read more →BFRIBiofrontera Files Label Extension for Ameluz in EU to include Treatment of Actinic Keratosis on Extremities and Trunk/Neck
Leverkusen, Germany, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, has filed a label extension for Ameluz® with the European Medicines Agency (EMA) on August 28, 2019 to
Read more →BFRIBiofrontera to participate at the Lake Street Capital Markets 2019 Best Ideas Growth (BIG) Conference
Leverkusen, Germany, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be participating in the Lake Street Capital Markets 2019 Best Ideas Growth (BIG) Conference, held
Read more →BFRIBiofrontera shows robust growth during first six months of 2019
Leverkusen, Germany, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its results for the first six months ended June 30, 2019. At the same time, Biofrontera
Read more →BFRIBiofrontera Announces Conference Call on August 27, 2019 to Discuss Half-year 2019 Financial Results
Leverkusen, Germany, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2019 on August 27, 2019
Read more →BFRIBiofrontera provides update on Cutanea integration
Leverkusen, Germany, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, provides an update on the integration progress of Cutanea Life Sciences, Inc. (“Cutane
Read more →BFRIBiofrontera reports preliminary unaudited sales revenue for the first six months of 2019
Leverkusen, Germany, July 09, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-group”), an international biopharmaceutical company, today reports preliminary unaudited revenue for the first six months of fisc
Read more →BFRIBiofrontera to Present at Two Upcoming Investor Conferences
Leverkusen, Germany, June 12, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that Thomas Schaffer, Biofrontera’s Chief Financial Officer, is scheduled to present at
Read more →BFRIBiofrontera nominates new candidate for the Supervisory Board
Leverkusen, Germany, June 04, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that the agenda for the Annual General Meeting to be held on July 10, 2019 has been pub
Read more →BFRIBiofrontera Reports First Quarter 2019 Financial Results
Leverkusen, Germany, May 29, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2019 and provided an update o
Read more →BFRIBiofrontera Announces Conference Call on May 29, 2019 to Discuss First Quarter 2019 Financial Results
Leverkusen, Germany, May 16, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first quarter ended March 31, 2019 on May 29, 2019. Con
Read more →BFRIBiofrontera Reports Full Year 2018 Financial Results
Leverkusen, Germany, April 29, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the full year ended December 31, 2018 and provided an update
Read more →BFRIBiofrontera AG to hold extraordinary shareholders’ meeting on 15 May 2019
Leverkusen, Germany, April 26, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced in the Federal Gazette that it will hold an extraordinary shareholders' meeting on 15
Read more →BFRIBiofrontera reports further positive results from the phase III trial with Ameluz for photodynamic therapy of actinic keratoses on the extremities and trunk/neck
Leverkusen, Germany, April 16, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports positive results for the secondary endpoints of its Phase III clinical trial evaluating
Read more →BFRIBiofrontera Announces Conference Call on April 29, 2019 to Discuss 2018 Financial Results
Leverkusen, Germany, April 16, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the full financial year ended December 31, 2018 on April 2
Read more →BFRIBiofrontera reports preliminary unaudited sales revenue for the first three months of 2019
Leverkusen, Germany, April 15, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports preliminary unaudited revenue for the first three months of fiscal year 2019. The preli
Read more →BFRIBiofrontera provides information on the announced voluntary public tender offer by Maruho Deutschland GmbH
Leverkusen, Germany, April 02, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, informs about the announced voluntary public tender offer by Maruho Deutschland GmbH. Maruho Deutschl
Read more →BFRIBiofrontera provides corporate update; conference call details for March 26, 2019
Leverkusen, Germany, March 25, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces a conference call to be held tomorrow to provide a detailed corporate update on its acquisit
Read more →BFRIBiofrontera, Inc., USA, acquires Cutanea Life Sciences, Inc., USA
Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 25, 2019 (GLOBE NEWSWIRE) -- Biofrontera Inc., USA (“Biofrontera”), a wholly owned subsidiary of Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), today entered into an agreement to acquire all shar
Read more →BFRIBiofrontera Reports Positive Phase III Results with Ameluz for photodynamic therapy of actinic keratoses on the extremities and trunk/neck
Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 20, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today received positive preliminary results for the primary endpoint of its Ph
Read more →BFRIBiofrontera AG and Maruho Co., Ltd. conclude cooperation agreement regarding branded generics and plan collaboration on expansion of indications and distribution of Ameluz
Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 19, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), today signed an agreement to continue the expired research cooperation with Maruho Co., Ltd., Osaka, Japan (“Maruho”) r
Read more →BFRIBiofrontera Honored with Prestigious Silver Stevie(R) Award for Outstanding U.S. Customer Service Department of the Year
Leverkusen, Germany, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced that its wholly owned US-subsidiary Biofrontera Inc. earned a Silver Stevie Award for o
Read more →BFRIBiofrontera implements new Falsified Medicines Directive
Leverkusen, Germany, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, has implemented all necessary safety measures defined in the new Commission Delegated Regulation (EU) 2
Read more →BFRIBiofrontera announces preliminary unaudited sales revenue and updates consolidated net income guidance for the full year 2018
Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), an international biopharmaceutical company, today announced preliminary unaudited revenue for the full fiscal year 2018
Read more →BFRIBiofrontera receives FDA approval for upscaling of batch size for Ameluz production
Leverkusen, Germany, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA), and earlier the European Medicines Ag
Read more →BFRIBiofrontera to Participate in Two Upcoming Investor Conferences
Leverkusen, Germany, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced its participation in two upcoming conferences. Prof. Dr. Hermann Lübbert, Biofrontera’
Read more →BFRIBiofrontera reports earnings results for the third quarter and first nine months of 2018
Leverkusen, Germany, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2018 and provided an updat
Read more →BFRIBiofrontera Announces Conference Call to Discuss Q3 2018 Financial Results
Leverkusen, Germany, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the 9-month period ended September 30, 2018 on November 16,
Read more →BFRIBiofrontera to Present at the 4th Annual Dawson James Small Cap Growth Stock Conference
Leverkusen, Germany, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced that Dr. Hermann Lübbert, Biofrontera’s Chief Executive Officer, is scheduled to present at the 4th Ann
Read more →BFRIBiofrontera announces preliminary unaudited sales revenue for the first nine months of 2018 and increases revenue guidance
Leverkusen, Germany, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), an international biopharmaceutical company, today announced preliminary unaudited revenue for the first nine months of fiscal year 2018 and increases its revenu
Read more →BFRIBiofrontera starts patient recruitment for U.S. Phase III Trial Evaluating Ameluz / BF-RhodoLED for Superficial Basal Cell Carcinoma
Enrollment of 186 patients at 12 study sites in the U.S. started Phase III trial completion for photodynamic therapy of superficial basal cell carcinoma expected in first half of 2020 Filing for approval with the FDA anticipated in second half of 2020 Leverkusen, Germany, Sept
Read more →BFRIBiofrontera to Present at the Cantor Fitzgerald Global Healthcare Conference
Leverkusen, Germany, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced that Thomas Schaffer, Biofrontera’s Chief Financial Officer, is scheduled to present at the Cantor Fit
Read more →BFRIBiofrontera uses the long summer months to introduce daylight photodynamic therapy (PDT) with Ameluz in the EU
Leverkusen, Germany, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced an update on preliminary EU sales figures for the sunny months of April to August, following the marke
Read more →BFRIBiofrontera files lawsuit against W.K.T. Zours, Deutsche Balaton AG and further defendants
Leverkusen, Germany, June 12, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that it has filed a complaint in the United States District Court for the Southern Dist
Read more →BFRIBiofrontera Reports First Quarter 2018 Financial Results
Leverkusen, Germany, May 30, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2018 and provided an update o
Read more →BFRIBiofrontera Reports Full Year 2017 Financial Results
Leverkusen, Germany, April 30, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, today reported its consolidated financial results for the full year ended December 3
Read more →BFRIBiofrontera announces preliminary unaudited sales revenues for the 1st Quarter 2018
Leverkusen, Germany, April 12, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA) (ISIN: DE0006046113), the specialist for the treatment of sun-induced skin cancer, today announced preliminary unaudited revenue for the first quarter of fiscal year 2018. The preliminary unaudi
Read more →BFRIBiofrontera AG Announces Partial Waiver of Lock-Up Agreement
LEVERKUSEN, Germany, March 15, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA) (Frankfurt Stock Exchange:B8F) (the “Company”) announced today that The Benchmark Company, LLC, the managing underwriter of the Company’s recent initial public offering in the United States of 1,
Read more →BFRIBiofrontera AG Announces Closing of $US12.9 Million Firm Commitment Initial Public Offering of American Depositary Shares
LEVERKUSEN, Germany, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA) (Frankfurt Stock Exchange:B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, today announced the closing of a U.S. firm commitment underwritten public offering of A
Read more →BFRIBiofrontera AG (Nasdaq: BFRA) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (Nasdaq:BFRA), the specialist for the treatment of sun-induced skin cancer, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Prof. Hermann Lübbert, PhD, Chief Executive Officer, will ring the
Read more →BFRIBiofrontera AG Announces Pricing of US$12 Million Firm Commitment Public Offering of American Depositary Shares and NASDAQ Listing
LEVERKUSEN, Germany, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA) (Frankfurt Stock Exchange:B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, today announced the pricing of a U.S. underwritten public offering of 1,215,000 America
Read more →BFRIBiofrontera AG: Biofrontera Reports Full Year 2015 Financial Results
LEVERKUSEN, Germany, April 15, 2016 (GLOBE NEWSWIRE) -- Biofrontera AG (FSE: B8F), the specialist for sun-induced skin cancer, today reported its full year 2015 financial results for the year ended 31 December 2015. - New Drug Application (NDA) for BF-200 ALA in U.S. remains on
Read more →BFRIBiofrontera AG: Notice of Annual Results 2016
LEVERKUSEN, Germany, April 7, 2016 (GLOBE NEWSWIRE) -- Biofrontera AG (AIM:B8F), the specialist for sun-induced skin cancer, will be announcing its financial results for the twelve-month period ended 31 December 2015 on 15 April 2016. Conference calls for shareholders and intere
Read more →BFRIBiofrontera Announces NDA Progress Update for BF-200 ALA
FDA issued suggested labeling for BF-200 ALA for treatment of actinic keratosis (AK) FDA has not requested any further data LEVERKUSEN, Germany, April 4, 2016 (GLOBE NEWSWIRE) -- Biofrontera AG (FSE: B8F), the specialist for sun-induced skin cancer, today announced an update on
Read more →BFRIBiofrontera AG: Biofrontera AG resolves on capital increase
Leverkusen, Germany, Feb. 16, 2016 (GLOBE NEWSWIRE) -- The Management Board of Biofrontera AG (FSE: B8F) has resolved on 12 February 2016, with the approval of the Supervisory Board, to increase the registered share capital of the Company by up to EUR 2,357,384 from authorized ca
Read more →BFRIBiofrontera AG: Pivotal Phase III Data Demonstrate Significant Efficacy and Excellent Safety for BF-200 ALA Treatment of Superficial Skin Cancer
LEVERKUSEN, Germany, Feb. 11, 2016 (GLOBE NEWSWIRE) -- Biofrontera AG (FSE: B8F), the specialist for sun-induced skin cancer, presents data from three pivotal Phase III trials for its lead drug candidate BF-200 ALA at the 14th Annual South Beach Symposium. The studies demonstrate
Read more →Competitive Position
How BFRI ranks across every disease it competes inCompetitive Position is a premium feature
See how BFRI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial